CN1913890A - 大体上不含半乳甘露聚糖且含有哌拉西林(piperacillin)和他唑巴坦(tazobactam)的组合物 - Google Patents

大体上不含半乳甘露聚糖且含有哌拉西林(piperacillin)和他唑巴坦(tazobactam)的组合物 Download PDF

Info

Publication number
CN1913890A
CN1913890A CNA200580003211XA CN200580003211A CN1913890A CN 1913890 A CN1913890 A CN 1913890A CN A200580003211X A CNA200580003211X A CN A200580003211XA CN 200580003211 A CN200580003211 A CN 200580003211A CN 1913890 A CN1913890 A CN 1913890A
Authority
CN
China
Prior art keywords
piperacillin
tazobactam
pharmaceutical composition
galactomannan
filter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200580003211XA
Other languages
English (en)
Chinese (zh)
Inventor
马克·爱德华·鲁彭
王玉芬
萨姆·马特阿卡·乔治
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN1913890A publication Critical patent/CN1913890A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA200580003211XA 2004-01-30 2005-01-27 大体上不含半乳甘露聚糖且含有哌拉西林(piperacillin)和他唑巴坦(tazobactam)的组合物 Pending CN1913890A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54091004P 2004-01-30 2004-01-30
US60/540,910 2004-01-30

Publications (1)

Publication Number Publication Date
CN1913890A true CN1913890A (zh) 2007-02-14

Family

ID=34837439

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200580003211XA Pending CN1913890A (zh) 2004-01-30 2005-01-27 大体上不含半乳甘露聚糖且含有哌拉西林(piperacillin)和他唑巴坦(tazobactam)的组合物

Country Status (7)

Country Link
US (1) US20050171077A1 (enExample)
EP (1) EP1711178A1 (enExample)
JP (1) JP2007519747A (enExample)
KR (1) KR20060127931A (enExample)
CN (1) CN1913890A (enExample)
CA (1) CA2553038A1 (enExample)
WO (1) WO2005074925A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103006676A (zh) * 2012-12-27 2013-04-03 石药集团中诺药业（石家庄）有限公司 新型哌拉西林他唑巴坦组合物
CN113209030A (zh) * 2021-04-27 2021-08-06 海南通用康力制药有限公司 哌拉西林钠他唑巴坦钠无菌粉针剂的制备方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1787641A1 (de) * 2005-11-22 2007-05-23 Helm AG Tazobactam-Piperacillin-Lyophilisat
ATE485043T1 (de) * 2005-12-05 2010-11-15 Sandoz Ag Verfahren zur herstellung von lyophilisiertem piperacillin-natrium in kombination mit tazobactam-natrium, mit verbesserter stabilität nach der rekonstitution
ITMI20070568A1 (it) * 2007-03-22 2008-09-23 Acs Dobfar Spa Comosizione farmaceutica sterile iniettabile avente piperacillina sodica e tazobactam sodico come principi attivi
EP3616695B1 (en) 2011-09-09 2024-10-23 Merck Sharp & Dohme LLC Ceftolozane/tazobactam for treating intrapulmonary infections
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
US9320740B2 (en) 2013-03-15 2016-04-26 Merck Sharp & Dohme Corp. Ceftolozane-tazobactam pharmaceutical compositions
US20140274995A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Parenteral ceftolozane antibiotic compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
AU2014233637A1 (en) 2013-09-09 2015-03-26 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477452A (en) * 1981-03-26 1984-10-16 American Cyanamid Company Composition of matter comprising a lyophilized preparation of a penicillin derivative
US4534977A (en) * 1981-03-26 1985-08-13 American Cyanamid Company Composition of matter comprising a low bulk density lyophilized preparation of Sodium Piperacillin
US4562073A (en) * 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
AUPQ137699A0 (en) * 1999-07-02 1999-07-22 University Of New England, The Control of acidosis
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
AU2003230899A1 (en) * 2003-04-14 2004-11-26 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103006676A (zh) * 2012-12-27 2013-04-03 石药集团中诺药业（石家庄）有限公司 新型哌拉西林他唑巴坦组合物
CN103006676B (zh) * 2012-12-27 2015-02-25 石药集团中诺药业（石家庄）有限公司 新型哌拉西林他唑巴坦组合物
CN113209030A (zh) * 2021-04-27 2021-08-06 海南通用康力制药有限公司 哌拉西林钠他唑巴坦钠无菌粉针剂的制备方法

Also Published As

Publication number Publication date
CA2553038A1 (en) 2005-08-18
US20050171077A1 (en) 2005-08-04
WO2005074925A1 (en) 2005-08-18
JP2007519747A (ja) 2007-07-19
KR20060127931A (ko) 2006-12-13
WO2005074925A8 (en) 2005-12-08
EP1711178A1 (en) 2006-10-18

Similar Documents

Publication Publication Date Title
CN1913890A (zh) 大体上不含半乳甘露聚糖且含有哌拉西林(piperacillin)和他唑巴坦(tazobactam)的组合物
US10415076B2 (en) High throughput quantification and characterization of foot and mouth disease virus and products thereof
CN1087724A (zh) 前处理剂、前处理方法、使用经前处理的试样的测定法、测定用药盒以及感染症的诊断方法
US20220348986A1 (en) Methods and compositions for comprehensive and high sensitivity detection of pathogens and drug resistance markers
CN119064246A (zh) 用于评估生物材料中的流感病毒类型的非缔合的病毒尺寸颗粒的流式细胞术方法
CN101074962A (zh) Abo血型反定型试剂
CN1350459A (zh) 适用于治疗老年性痴呆的平均分子量为2400d的糖胺聚糖
CN1119414A (zh) 稳定化的药物组合物及其制备方法
CN1440980A (zh) 甘露聚糖肽及其制备工艺和用途
CN1857434A (zh) 一种新复方大青叶制剂的质量控制方法
HK1097199A (en) Compositions substantially free of galactomannan containing piperacillin and tazobactam
CN1266477C (zh) 一种体外血型血清学实验检定方法
Gu et al. A new method aimed to quickly identify pathogen and drug susceptibility test based on matrix-assisted laser desorption/ionization time of flight mass spectrometry combined with flow cytometry
CN1188530C (zh) Sars病毒的基因检测试剂盒及检测方法
CN1785166A (zh) 小儿氨酚烷胺制剂的质量控制方法
CN110878374B (zh) 药品质量控制中常见产毒真菌的特征序列鉴定方法
CN1194678C (zh) 硫普罗宁冻干粉针注射剂
CN1785295A (zh) 一种中药制剂的质量控制方法
Mantadakis et al. Encephalopathy complicated by Guillain-Barre syndrome and hydrocephalus and associated with acute Bartonella quintana infection
CN1253175C (zh) 一种药物组合物、其制备方法及其用途
CN120193045B (zh) 一种结核分枝杆菌药敏试剂盒及其方法和应用
CN1300318C (zh) 一种编码丝状支原体丝状亚种n端脂蛋白的dna
CN1752107A (zh) 一种抗apoA I、apoB抗体制备方法以及用于检测apoA I、apoB的试剂盒
CN111138523A (zh) 一种从重组鸡干扰素α复性液中纯化制备重组鸡干扰素α的方法
CN1686098A (zh) 硫普罗宁冻干粉针注射剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1097199

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070214

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1097199

Country of ref document: HK